checkAd

    DGAP-Adhoc  130  0 Kommentare Merck KGaA: Merck KGaA reverses provision for lawsuit in the amount of EUR 365 million

    DGAP-Ad-hoc: Merck KGaA / Key word(s): Miscellaneous
    Merck KGaA: Merck KGaA reverses provision for lawsuit in the amount of EUR 365 million

    29-Sep-2020 / 18:06 CET/CEST
    Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.



    Darmstadt, September 29, 2020. In the United States Merck KGaA's subsidiary EMD Serono, Inc. (Merck) is involved in a US patent dispute with Biogen Inc., United States (Biogen). Biogen sued Merck for damages in connection with a patent infringement caused by Merck's product Rebif before the U.S. District Court New Jersey, Newark. Merck defended itself against the allegations and brought a countersuit claiming that Biogen's patent is invalid. In February 2018 a jury declared Biogen's patent invalid vis-à-vis Merck. The jury verdict was overturned by the District Court Judge, who upheld the validity of Biogen's patent. Merck filed a complaint with the U.S. Court of Appeals for the Federal Circuit against this ruling.

    On 28 September 2020 the U.S. Court of Appeals for the Federal Circuit set aside the decision of the District Court Judge, invalidated Biogen's patent and instructed the District Court to reinstate the jury verdict.

    Therefore, Merck KGaA has decided today to reverse the provisions for the patent dispute proceedings in the amount of EUR 365 million. Thereof, up to a mid to high double-digit million amount might be booked into the financial result.
    Merck KGaA will adjust its forecasts accordingly as part of its regular financial reporting

    Friederike Segeberg, Leiterin News & Reputation
    Merck KGaA
    Frankfurter Straße 250
    64293 Darmstadt
    Germany
    Phone: +49 6151 72 - 6328
    Fax: +49 6151 72 - 913321
    Email: investor.relations@merckgroup.com
    Internet: www.merck.de
    ISIN: DE0006599905
    WKN: 659990
    Indices: DAX
    Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX

    29-Sep-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de


    Language: English
    Company: Merck KGaA
    Frankfurter Str. 250
    64293 Darmstadt
    Germany
    Phone: +49 (0)6151 72 - 6328
    E-mail: Friederike.Segeberg@merckgroup.com
    Internet: https://www.merckgroup.com/de
    ISIN: DE0006599905
    WKN: 659990
    Indices: DAX
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX
    EQS News ID: 1137699

     
    End of Announcement DGAP News Service

    1137699  29-Sep-2020 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1137699&application_name=news&site_id=wallstreet


    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Merck KGaA: Merck KGaA reverses provision for lawsuit in the amount of EUR 365 million DGAP-Ad-hoc: Merck KGaA / Key word(s): Miscellaneous Merck KGaA: Merck KGaA reverses provision for lawsuit in the amount of EUR 365 million 29-Sep-2020 / 18:06 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation …

    Schreibe Deinen Kommentar

    Disclaimer